Testosterone replacement therapy and polycythemia in HIV-infected patients

Charles Kyriakos Vorkas*, Carlos M. Vaamonde and Marshall J. Glesby

We conducted a case–control study to assess testosterone use as a primary risk factor for polycythemia in 21 HIV-infected men. Any testosterone use within 2 months of first elevated hemoglobin was associated with polycythemia (matched odds ratio 6.55; 95% confidence interval 1.83–23.4; \( P = 0.004 \)) and intramuscular administration demonstrated a stronger association than topical use. No adverse cardiovascular or thrombotic events were observed. HIV-infected patients taking testosterone should undergo routine hematologic monitoring with adjustment of therapy when appropriate.

HIV can be complicated by hematologic abnormalities, most commonly anemia, thrombocytopenia and granulocytopenia [1,2]. Reporting of HIV-associated polycythemia is rare [3,4]. Case reports [1,2,5–7] and one series [3] raise the possibility of an association between HIV infection and myeloproliferative disorders. Notably, some patients described in the literature meet criteria for polycythemia vera [2,4,5]. Certain case reports demonstrate resolution of polycythemia with zidovudine [1,6,7] and one paradoxically reports zidovudine-induced polycythemia [8].

The association between testosterone-replacement therapy and polycythemia has been well described [9–11]. Intramuscular testosterone is associated with a higher risk for polycythemia than topical administration [9]. Smoking has also been associated with polycythemia and may contribute to the effects of other risk factors [3,9,12]. However, little is known about the mechanisms of polycythemia in HIV [3]. We conducted a case–control study to test the hypothesis that testosterone use is the primary risk factor for polycythemia in HIV-infected patients.

The Center for Special Studies at New York–Presbyterian Hospital–Weill Cornell Medical Center is a multidisciplinary clinic established in 1988 for the care of people living with HIV/AIDS. We retrospectively reviewed the clinic’s electronic medical record (EMR) for patients with polycythemia from 1988–2008. Polycythemia was defined as a sustained (≥8 weeks) hemoglobin value of at least 18.5 g/dl for men and at least 16.5 g/dl for women [13]. Two controls per case were randomly selected from the group of clinical patients matched on sex, age ± 5 years, date of initial clinical visit ± 6 months and duration of clinical follow-up equal to or greater than the case’s follow-up at time of polycythemia diagnosis. Clinical and laboratory data were extracted onto standardized case report forms. The EMR was further reviewed for information on Hepatitis C coinfection, smoking history, zidovudine use, and testosterone-replacement therapy within 2 months of polycythemia diagnosis. Chart review was performed to identify adverse consequences of polycythemia, including cardiovascular or thrombotic events, and additional clinical conditions that may have contributed to elevated hemoglobin. Data were deidentified and entered into a customized Microsoft Access 2007 Database (Microsoft Corp., Redmond, Washington, USA) and analyzed using Stata, version 11.0 (Stata Corporation, College Station, Texas, USA). We performed univariate and multivariate conditional logistic regression to identify risk factors for polycythemia. This study was approved by the Institutional Review Board of Weill Cornell Medical College.

Twenty-five patients met criteria for polycythemia (21 men; four women). Using the number of unique patients with at least five clinical visits during the time frame of the study as the denominator (\( n = 6007 \)), the estimated prevalence of polycythemia was 0.42% (95% CI 0.27–0.61). Mean hemoglobin at diagnosis of polycythemia was 18.9 ± 0.42 g/dl in men and 17.0 ± 0.83 g/dl in women. Among the four female cases, one was diagnosed with chronic obstructive pulmonary disease (COPD) and severe pulmonary hypertension, whereas the other three did not have a documented explanation for elevated hemoglobin. Because of the relatively small number of female cases and primary hypothesis related to testosterone use, our case–control study focused on the 21 male patients.

The median year of diagnosis of polycythemia was 2005 (interquartile range 2002–2007). The mean age was 45.7 ± 8 years in cases and 46 ± 8.2 in controls. CD4 cell count and HIV RNA levels were similar among cases and controls (Table 1). Any testosterone use within 2 months of first elevated hemoglobin value was associated with polycythemia matched odds ratio (OR) 6.55; 95% confidence interval (CI) 1.83–23.4; \( P = 0.004 \). Testosterone was administered most commonly via the intramuscular route in cases and tended to be associated more strongly with polycythemia than was use of topical testosterone. There was a trend for an inverse association between current or recent zidovudine use and
polycythemia. In multivariate analysis, any testosterone use (OR 7.65; 95% CI 1.99–29.4; \( P = 0.003 \)) and zidovudine (OR 3.57; 95% CI 0.86–14.8; \( P = 0.078 \)) were independently associated with polycythemia, though only testosterone use demonstrated statistical significance.

Five of 21 (24%) cases did not use testosterone, but had other explanations for their polycythemia: pulmonary hypertension (1), COPD (2), and plasma volume contraction (2). In two of 21 cases (10%), there was no documented reason for elevated hemoglobin. No cases met criteria for polycythemia vera and no adverse cardiovascular or thrombotic events were noted among cases or controls.

To our knowledge, this study is the first systematic investigation of polycythemia in HIV-infected patients. In our analysis, testosterone use and smoking were associated with polycythemia. Although other causes of polycythemia were identified, testosterone use was the leading explanation of elevated hemoglobin in our patients. Notably, 10% of cases did not have a documented reason for elevated hemoglobin. No cases met criteria for polycythemia vera and no adverse cardiovascular or thrombotic events were noted among cases or controls.

Table 1. Univariate analysis of factors associated with polycythemia in HIV-infected patients.

<table>
<thead>
<tr>
<th></th>
<th>Cases (n = 21)</th>
<th>Controls (n = 42)</th>
<th>Matched odds ratio</th>
<th>95% CI</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 cell count</td>
<td>473 (248)</td>
<td>450 (237)</td>
<td>1.02</td>
<td>0.92–1.14</td>
<td>0.71</td>
</tr>
<tr>
<td>HIV RNA below level of quantification (%)</td>
<td>11 (52%)</td>
<td>25 (60%)</td>
<td>0.68</td>
<td>0.20–2.31</td>
<td>0.54</td>
</tr>
<tr>
<td>Log HIV RNA (mean (SD); copies/ml)</td>
<td>3.56 (0.90)</td>
<td>3.89 (1.06)</td>
<td>0.47</td>
<td>0.12–1.75</td>
<td>0.26</td>
</tr>
<tr>
<td>Hepatitis C co-infection (%)</td>
<td>6 (29%)</td>
<td>11 (26%)</td>
<td>1.13</td>
<td>0.34–3.70</td>
<td>0.84</td>
</tr>
<tr>
<td>Cigarette smoking(^c)</td>
<td>10 (48%)</td>
<td>16 (38%)</td>
<td>1.48</td>
<td>0.51–4.30</td>
<td>0.47</td>
</tr>
<tr>
<td>Zidovudine use(^c)</td>
<td>8 (38%)</td>
<td>8 (19%)</td>
<td>2.73</td>
<td>0.79–9.50</td>
<td>0.11</td>
</tr>
<tr>
<td>Any testosterone use(^c)</td>
<td>14 (67%)</td>
<td>9 (21%)</td>
<td>6.55</td>
<td>1.83–23.4</td>
<td>0.004</td>
</tr>
<tr>
<td>Topical testosterone(^c)</td>
<td>5 (24%)</td>
<td>3 (7%)</td>
<td>3.33</td>
<td>0.80–13.9</td>
<td>0.099</td>
</tr>
<tr>
<td>Intramuscular testosterone(^c)</td>
<td>10 (48%)</td>
<td>6 (14%)</td>
<td>4.33</td>
<td>1.34–14.0</td>
<td>0.015</td>
</tr>
</tbody>
</table>

\(^a\)Odds ratio is per 50 cells/mm\(^3\).
\(^b\)Log HIV RNA was calculated only for participants with measurable viremia (\( n = 10 \) cases and \( n = 17 \) controls).
\(^c\)Within 2 months of first elevated hemoglobin in cases or equivalent time point in controls.

CI, confidence interval.

Acknowledgements

M.J.G. conceived of the study. All authors contributed to the design of the study, performed chart reviews, participated in data analysis and interpretation of the results. C.K.V. wrote the initial draft of the manuscript. M.J.G. and C.M.V. reviewed and edited the manuscript. All authors have read and approved the text as submitted for publication.

Conflicts of interest

This study was supported in part by NIH/NIAID K24 AI078884. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

M.J.G. receives research support to Weill Cornell Medical College from Pfizer and serves as a consultant to Pfizer.

Department of Medicine, Weill Cornell Medical College, New York, New York, USA.

Department of Medicine, Weill Cornell Medical College, New York, New York, USA. Tel: +1 212 746 4177; fax: +1 212 746 8852; e-mail: mag2005@med.cornell.edu

*Current address: Department of Medicine, University of North Carolina School of Medicine at Chapel Hill.

Received: 18 July 2011; revised: 27 September 2011; accepted: 30 September 2011.

References


